{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T22:38:23Z","timestamp":1778625503255,"version":"3.51.4"},"reference-count":37,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2009,8,1]],"date-time":"2009-08-01T00:00:00Z","timestamp":1249084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nuclear Medicine and Biology"],"published-print":{"date-parts":[[2009,8]]},"DOI":"10.1016\/j.nucmedbio.2009.04.003","type":"journal-article","created":{"date-parts":[[2009,7,31]],"date-time":"2009-07-31T17:11:00Z","timestamp":1249060260000},"page":"659-669","source":"Crossref","is-referenced-by-count":38,"title":["Treatment of HER2-positive breast carcinomatous meningitis with intrathecal administration of \u03b1-particle-emitting 211At-labeled trastuzumab"],"prefix":"10.1016","volume":"36","author":[{"given":"Abraham","family":"Boskovitz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger E.","family":"McLendon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsunori","family":"Okamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John H.","family":"Sampson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darell D.","family":"Bigner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael R.","family":"Zalutsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nucmedbio.2009.04.003_bib1","series-title":"Cancer medicine","first-page":"1037","article-title":"Primary neoplasms of the central nervous system in adults","author":"Prados","year":"2006"},{"key":"10.1016\/j.nucmedbio.2009.04.003_bib2","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1200\/JCO.2005.01.131","article-title":"Neoplastic meningitis","volume":"23","author":"Chamberlain","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nucmedbio.2009.04.003_bib3","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1053\/j.seminoncol.2006.04.016","article-title":"Neoplastic meningitis from systemic malignancies: diagnosis, prognosis and treatment","volume":"33","author":"Jaeckle","year":"2006","journal-title":"Semin Oncol"},{"key":"10.1016\/j.nucmedbio.2009.04.003_bib4","first-page":"953","article-title":"Expression of the HER-2\/neu proto-oncogene in normal human adult and fetal tissues","volume":"5","author":"Press","year":"1990","journal-title":"Oncogene"},{"key":"10.1016\/j.nucmedbio.2009.04.003_bib5","first-page":"4087","article-title":"Overexpression of HER-2\/neu is associated with poor survival in advanced epithelial ovarian cancer","volume":"50","author":"Berchuck","year":"1990","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2009.04.003_bib6","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/ijc.2910450314","article-title":"Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues","volume":"45","author":"Natali","year":"1990","journal-title":"Int J Cancer"},{"key":"10.1016\/j.nucmedbio.2009.04.003_bib7","first-page":"60","article-title":"Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin)","volume":"26","author":"Sliwkowski","year":"1999","journal-title":"Semin Oncol"},{"key":"10.1016\/j.nucmedbio.2009.04.003_bib8","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0093-7754(01)90108-3","article-title":"Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer","volume":"28","author":"Hortobagyi","year":"2001","journal-title":"Semin Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.nucmedbio.2009.04.003_bib9","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/S0959-8049(00)00404-4","article-title":"Clinical trials of Herceptin (trastuzumab)","volume":"37","author":"Baselga","year":"2001","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.nucmedbio.2009.04.003_bib10","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1200\/JCO.2000.18.11.2349","article-title":"Trastuzumab in CSF","volume":"18","author":"Pestalozzi","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nucmedbio.2009.04.003_bib11","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/S1470-2045(06)70864-6","article-title":"Meningeal carcinomatosis from breast cancer treated with intrathecal trastuzumab","volume":"7","author":"Platini","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.nucmedbio.2009.04.003_bib12","first-page":"1373","article-title":"Application of intrathecal trastuzumab (Herceptin) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer","volume":"15","author":"Stemmler","year":"2006","journal-title":"Oncol Rep"},{"key":"10.1016\/j.nucmedbio.2009.04.003_bib13","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1526-8209(11)70419-0","article-title":"Use of intrathecal trastuzumab in a patient with carcinomatous meningitis","volume":"2","author":"Laufman","year":"2001","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.nucmedbio.2009.04.003_bib14","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1097\/CAD.0b013e32830b58b0","article-title":"Intrathecal trastuzumab (Herceptin) and methotrexate for meningeal carcinomatosis in HER-2 overexpressing metastatic breast cancer: a case report","volume":"19","author":"Stemmler","year":"2008","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.nucmedbio.2009.04.003_bib15","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1093\/annonc\/mdn654","article-title":"High dose intrathecal trastuzumab for leptomeningeal metastases secondary to HER-2-expressing breast cancer","volume":"19","author":"Mir","year":"2008","journal-title":"Annals Oncol"},{"issue":"Suppl","key":"10.1016\/j.nucmedbio.2009.04.003_bib16","first-page":"1043s","article-title":"Dosimetric model for antibody targeted radionuclide therapy of tumor cells in cerebrospinal fluid","volume":"50","author":"Millar","year":"1990","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2009.04.003_bib17","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2174\/1874471010801030177","article-title":"Astatine radiopharmaceuticals: prospects and problems","volume":"1","author":"Vaidyanathan","year":"2008","journal-title":"Curr Radiopharm"},{"key":"10.1016\/j.nucmedbio.2009.04.003_bib18","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/0969-8051(96)00021-2","article-title":"Chimeric anti-tenascin antibody 81C6: increased tumor localization compared with its murine parent","volume":"23","author":"Zalutsky","year":"1996","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2009.04.003_bib19","first-page":"1508","article-title":"High-level production of alpha-particle-emitting 211At and preparation of 211At-labeled antibodies for clinical use","volume":"42","author":"Zalutsky","year":"2001","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2009.04.003_bib20","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/BF01961241","article-title":"Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2\/neu","volume":"24","author":"Benz","year":"1993","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.nucmedbio.2009.04.003_bib21","first-page":"1954","article-title":"Activity of intrathecal 4-hydroperoxycyclo-phosphamide in a nude rat model of human neoplastic meningitis","volume":"50","author":"Fuchs","year":"1990","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2009.04.003_bib22","first-page":"5514","article-title":"Efficacy of intracerebral microinfusion of trastuzumab in an athymic rat model of intracerebral metastatic breast cancer","volume":"9","author":"Grossi","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2009.04.003_bib23","first-page":"963","article-title":"Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: Phase I trial results","volume":"2","author":"Brown","year":"1996","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.nucmedbio.2009.04.003_bib24","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1002\/1097-0142(20010501)91:9<1809::AID-CNCR1200>3.0.CO;2-L","article-title":"Long-term response in a patient with neoplastic meningitis secondary to melanoma treated with 131I-radiolabeled anti-chondroitin proteoglycan sulfate Me1-14 F(ab')2: a case study","volume":"91","author":"Cokgor","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.nucmedbio.2009.04.003_bib25","doi-asserted-by":"crossref","first-page":"5465","DOI":"10.1200\/JCO.2007.11.1807","article-title":"Phase I study of targeted radioimmunotherapy for leptomeningeal cancers using intra-Ommaya 131-I-3F8","volume":"25","author":"Kramer","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nucmedbio.2009.04.003_bib26","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1136\/jnnp.54.3.260","article-title":"Carcinomatous meningitis: antibody guided therapy with I-131 HMFG1","volume":"54","author":"Moseley","year":"1991","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.nucmedbio.2009.04.003_bib27","doi-asserted-by":"crossref","first-page":"6985","DOI":"10.1158\/1078-0432.CCR-04-0859","article-title":"Treatment of neuroblastoma meningeal carcinomatosis with intrathecal application of \u03b1-emitting atomic nanogenerators targeting disialo-ganglioside GD2","volume":"10","author":"Miederer","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.nucmedbio.2009.04.003_bib28","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.nucmedbio.2005.12.006","article-title":"In vitro cytotoxicity of 211At-labeled trastuzumab in human breast cancer cell lines: effect of specific activity and HER2 receptor heterogeneity on survival fraction","volume":"33","author":"Akabani","year":"2006","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2009.04.003_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/(SICI)1097-0215(19990219)84:1<1::AID-IJC1>3.0.CO;2-A","article-title":"Tumor-antigen heterogeneity of disseminated breast cancer cells: implications for immunotherapy of minimal residual disease","volume":"84","author":"Braun","year":"1999","journal-title":"Int J Cancer"},{"key":"10.1016\/j.nucmedbio.2009.04.003_bib30","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0022-3565(24)37211-8","article-title":"Pharmacokinetics of IgG and IgM anti-ganglioside antibodies in rats and monkeys after intrathecal administration","volume":"284","author":"Bergman","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.nucmedbio.2009.04.003_bib31","first-page":"4719","article-title":"Radioimmunotherapy of neoplastic meningitis in rats using an \u03b1-particle-emitting immunoconjugate","volume":"54","author":"Zalutsky","year":"1994","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2009.04.003_bib32","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0165-0270(02)00033-X","article-title":"Serial cerebrospinal fluid sampling in a rat model to study drug uptake from the nasal cavity","volume":"116","author":"van den Berg","year":"2002","journal-title":"J Neurosci Methods"},{"key":"10.1016\/j.nucmedbio.2009.04.003_bib33","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1176\/ajp.154.12.1648","article-title":"Sex differences in brain morphology in schizophrenia","volume":"154","author":"Nopoulos","year":"1997","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.nucmedbio.2009.04.003_bib34","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0360-3016(99)00206-0","article-title":"Radiotoxicity of systemically administered 211At-labeled human\/mouse chimeric monoclonal antibody: a long-term survival study with histological analysis","volume":"45","author":"McLendon","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.nucmedbio.2009.04.003_bib35","doi-asserted-by":"crossref","first-page":"30","DOI":"10.2967\/jnumed.107.046938","article-title":"Clinical experience with \u03b1-emitting astatine-211: treatment of recurrent brain tumor patients with 211At-labeled chimeric 81C6 anti-tenascin monoclonal antibody","volume":"49","author":"Zalutsky","year":"2008","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.nucmedbio.2009.04.003_bib36","doi-asserted-by":"crossref","first-page":"5907","DOI":"10.1158\/0008-5472.CAN-04-4472","article-title":"Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging","volume":"65","author":"Olafsen","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2009.04.003_bib37","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0969-8051(03)00005-2","article-title":"N-succinimidyl 3-[211At]astato-4-guanidinomethylbenzoate: an acylation agent for labeling internalizing antibodies with \u03b1-particle emitting 211At","volume":"30","author":"Vaidyanathan","year":"2003","journal-title":"Nucl Med Biol"}],"container-title":["Nuclear Medicine and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805109000870?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805109000870?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T16:00:15Z","timestamp":1739289615000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969805109000870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["S0969805109000870"],"URL":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2009.04.003","relation":{},"ISSN":["0969-8051"],"issn-type":[{"value":"0969-8051","type":"print"}],"subject":[],"published":{"date-parts":[[2009,8]]}}}